MannKind price target lowered to $6 from $7 at Truist

Truist lowered the firm’s price target on MannKind (MNKD) to $6 from $7 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm sees a robust catalyst path, which could spark momentum for shares, with peds Afrezza label expansion PDUFA set for May 29, 2026, Furoscix ReadyFlow autoinjector PDUFA on July 26, and developmental updates for MNKD-201 in IPF – Part 1 of the phase 1b INFLO study anticipated to be completed this month, Truist added.